Symbicort

Drug Status: Marketed Drug

Symbicort provides the inhaled corticosteroid budesonide (Pulmicort) and the rapid and long-acting bronchodilator formoterol (Oxis) in a single inhaler (Turbuhaler).

Symbicort is indicated for the maintenance treatment of asthma in adults and children aged 6 years and above, where the combination of an inhaled corticosteroid and a long-acting beta 2- agonist is appropriate.

For further information on Symbicort and links to other product specific and disease area websites please click here.

Please consult the prescribing information for the country concerned on the approved use of drug. 

There are a number of ways to help you find trial information.  By using these filters you can find (i) recruiting status, (ii) therapy area, (iii) product and/or (iv) phase of drug development.  You can use one or all filters to identify your specific needs.

When a trial completes the results are reported here no later than one year after completion – this is why you may sometimes find that a Report is unavailable when you are searching through ‘closed’ trials.